NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences Ltd (NYSE:MYOV) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.07. View Myovant Sciences' Earnings History.

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Myovant Sciences.

8 Wall Street analysts have issued 12-month price objectives for Myovant Sciences' stock. Their forecasts range from $20.00 to $34.00. On average, they anticipate Myovant Sciences' share price to reach $26.00 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

News stories about MYOV stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myovant Sciences earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Myovant Sciences.

Myovant Sciences saw a drop in short interest in November. As of November 29th, there was short interest totalling 3,140,000 shares, a drop of 28.8% from the November 14th total of 4,410,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 9.8% of the shares of the stock are sold short. View Myovant Sciences' Current Options Chain.

Some companies that are related to Myovant Sciences include Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Intercept Pharmaceuticals (ICPT), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Evotec (EVTCY), Alkermes (ALKS), GW Pharmaceuticals PLC- (GWPH) and HUTCHISON CHINA/S (HCM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Exelixis (EXEL), Fate Therapeutics (FATE), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Uniqure (QURE), SCYNEXIS (SCYX) and Energy Transfer LP Unit (ET).

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (5.24%), Great Point Partners LLC (0.36%), Point72 Asset Management L.P. (0.23%), LVW Advisors LLC (0.13%), State Street Corp (0.06%) and Millennium Management LLC (0.05%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and Millennium Management LLC. View Insider Buying and Selling for Myovant Sciences.

MYOV stock was purchased by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Great Point Partners LLC, LVW Advisors LLC, State Street Corp, Virginia Retirement Systems ET AL, Tower Research Capital LLC TRC and Barclays PLC. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $15.73.

Myovant Sciences has a market capitalization of $1.41 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

The official website for Myovant Sciences is http://www.myovant.com/.

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]